Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations

Psychiatric Services

Volumn 66, Issue 2, 2015, Pages 127-133

  Velligan, Dawn I ^a   Carroll, Cathy ^b,c   Lage, Maureen J ^d   Fairman, Kathleen ^e  

^a University of Texas Health Science Center   (United States)

^b Xcenda   (United States)

^c Teva Pharmaceuticals   (United States)

^d HealthMetrics Outcomes Research   (United States)

^e Kathleen Fairman LTD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; COMORBIDITY; COST CONTROL; DRUG COST; DRUG UTILIZATION; EMERGENCY WARD; FEMALE; GROUPS BY AGE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL DISEASE; MONOTHERAPY; OUTCOME ASSESSMENT; POLYPHARMACY; RACE; SCHIZOPHRENIA; SEX; ADOLESCENT; MIDDLE AGED; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; MALE; MEDICAID; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POLYPHARMACY; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

EID: 84922278801     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201300085     Document Type: Article

References (36)

1. Kane JM, Leucht S, Carpenter D, et al: The Expert Consensus Guideline Series: optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. Journal of Clinical Psychiatry 64(suppl 12):5-19, 2003
2. Miller A, Hall CS, Buchanan RW, et al: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Journal of Clinical Psychiatry 65:500-508, 2004
3. Goodwin G, Fleischhacker W, Arango C, et al: Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. European Neuropsychopharmacology 19:520-532, 2009
4. Gilmer TP, Dolder CR, Folsom DP, et al: Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatric Services 58:1007-1010, 2007
5. Pickar D, Vinik J, Bartko JJ: Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS ONE 3:e3150, 2008
6. Xiang YT, Wang CY, Si TM, et al: Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009). Pharmacopsychiatry 45:7-12, 2012
7. Faries D, Ascher-Svanum H, Zhu B, et al: Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 5:26, 2005
8. Clark RE, Bartels SJ, Mellman TA, et al: Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophrenia Bulletin 28:75-84, 2002
9. Ganguly R, Kotzan JA, Miller LS, et al: Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry 65:1377-1388, 2004
10. Tsutsumi C, Uchida H, Suzuki T, et al: The evolution of antipsychotic switch and polypharmacy in natural practice: a longitudinal perspective. Schizophrenia Research 130:40-46, 2011
11. Sernyak MJ, Rosenheck R: Clinicians' reasons for antipsychotic coprescribing. Journal of Clinical Psychiatry 65:1597-1600, 2004
12. Tapp A, Wood AE, Secrest L, et al: Combination antipsychotic therapy in clinical practice. Psychiatric Services 54:55-59, 2003
13. Schumacher JE, Makela EH, Griffin HR: Multiple antipsychotic medication prescribing patterns. Annals of Pharmacotherapy 37: 951-955, 2003
14. McEvoy JP, Lieberman JA, Stroup TS, et al: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163:600-610, 2006
15. Lewis SW, Barnes TR, Davies L, et al: Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32:715-723, 2006
16. Guideline Summary NGC-3572: Practice Guideline for the Treatment of Patients With Schizophrenia, 2nd ed. Rockville, Md, Agency for Healthcare Research and Quality, National Guideline Clearinghouse, May 20, 2011. Available at guidelines.gov/content.aspx?id=5217
17. Marder SR: Can clinical practice guide a research agenda? Schizophrenia Bulletin 28:127-129, 2002
18. Fayek M, Flowers C, Signorelli D, et al: Psychopharmacology: underuse of evidence-based treatments in psychiatry. Psychiatric Services 54:1453-1454, 1456, 2003
19. Lewis S, Lieberman J: CATIE and CUtLASS: can we handle the truth? British Journal of Psychiatry 192:161-163, 2008
20. Taylor DM, Young C, Paton C: Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. Journal of Clinical Psychiatry 64:30-34, 2003
21. Howes OD, Vergunst F, Gee S, et al: Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. British Journal of Psychiatry 201:481-485, 2012
22. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 40:373-383, 1987
23. Perkins DO, Gu H, Weiden PJ, et al: Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. Journal of Clinical Psychiatry 69:106-113, 2008
24. Hudson TJ, Owen RR, Thrush CR, et al: A pilot study of barriers to medication adherence in schizophrenia. Journal of Clinical Psychiatry 65:211-216, 2004
25. Roh D, Chang JG, Kim CH, et al: Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Australian and New Zealand Journal of Psychiatry 48:52-60, 2014
26. Essock SM, Schooler NR, Stroup TS, et al: Effectiveness of switching from antipsychotic polypharmacy to monotherapy. American Journal of Psychiatry 168:702-708, 2011
27. Hori H, Yoshimura R, Katsuki A, et al: Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients. Journal of Psychiatric Research 47:1843-1848, 2013
28. Katona L, Czobor P, Bitter I: Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary. Schizophrenia Research 152:246-254, 2014
29. Manuel JI, Essock SM, Wu Y, et al: Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees. Psychiatric Services 63:1146-1149, 2012
30. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005
31. Paranthaman R, Baldwin RC: Survey of clozapine use by consultant old age psychiatrists. Psychiatrist 30:410-412, 2006
32. Nielsen J, Dahm M, Lublin H, et al: Psychiatrists' attitude towards and knowledge of clozapine treatment. Journal of Psychopharmacology 24:965-971, 2010
33. Correll CU, Shaikh L, Gallego JA, et al: Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophrenia Research 131:58-62, 2011
34. Essock SM, Schooler NR, Stroup TS, et al: Schizophrenia Trials Network: effectiveness of switching from antipsychotic polypharmacy to monotherapy. American Journal of Psychiatry 168:702-708, 2011
35. Lewis SW, Barnes TRE, Davies L, et al: Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 32:715-723, 2006
36. Meltzer HY, Alphs L, Green AI, et al: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Archives of General Psychiatry 60:82-91, 2003